Single-cell sequencing demonstrated that JS-201 reduced fibroblast proliferation by inhibiting the TGF-β/Smad pathway and the release of neutrophil extracellular traps mediated by ROS, thereby relieving radiation-induced pulmonary fibrosis. In conclusion, the JS-201 and radiotherapy combination enhances antitumor effects while mitigating acute and chronic RILI, and it may have potential for translational investigation as a cancer treatment strategy.

10 months ago

Journal

TGFB1 (Transforming Growth Factor Beta 1)

JS201

1year

JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer (clinicaltrials.gov)

P2, N=30, Recruiting, Hunan Province Tumor Hospital | Trial primary completion date: Jun 2024 --> Dec 2024

1 year ago

Trial primary completion date

PD-L1 (Programmed death ligand 1)

Lenvima (lenvatinib) • JS201

almost2years

JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer (clinicaltrials.gov)

P2, N=30, Recruiting, Hunan Province Tumor Hospital | Trial completion date: Jun 2023 --> Jun 2025 | Trial primary completion date: Jun 2022 --> Jun 2024

almost 2 years ago

Trial completion date • Trial primary completion date

PD-L1 (Programmed death ligand 1)

Lenvima (lenvatinib) • JS201

over4years

Clinical Study of JS201 in Patients With Advanced Malignant Tumors (clinicaltrials.gov)

P1, N=174, Recruiting, Shanghai Junshi Bioscience Co., Ltd.

over 4 years ago

Clinical • New P1 trial

PD-1 (Programmed cell death 1) • TGFB1 (Transforming Growth Factor Beta 1)

JS201

over4years

JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer (clinicaltrials.gov)

P2, N=30, Recruiting, Hunan Province Tumor Hospital

over 4 years ago

Clinical • New P2 trial

PD-L1 (Programmed death ligand 1)

Lenvima (lenvatinib) • JS201